Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 5/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PTPRC | P08575 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12362490 | 0.86 | CALCRL (0.55) | CALCRLRAB9AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL12020653 | 0.84 | CALCRL (0.55) | CALCRLRAB9ANPC1MAPTLMNA | |
| SCHEMBL12362409 | 0.79 | CALCRL (0.45) | CALCRL | |
| SCHEMBL12377500 | 0.74 | RAB9A (0.55) | RAB9ANPC1ALDH1A1KDM4EHPGD | |
| SCHEMBL846246 | 0.74 | ADM2 (0.63) | CALCRL | |
| SCHEMBL14233060 | 0.74 | CALCRL (0.58) | CALCRLMAPTTP53LMNA | |
| SCHEMBL12362515 | 0.73 | CALCRL (0.60) | CALCRLALDH1A1MAPTTP53LMNA | |
| SCHEMBL12655225 | 0.72 | CALCRL (0.63) | CALCRLRAB9ANPC1ALDH1A1KDM4E | |
| SCHEMBL12362509 | 0.72 | CALCRL (0.74) | CALCRL | |
| SCHEMBL21084102 | 0.72 | CRBN (0.41) | CALCRLRAB9ANPC1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989624-B2 | Aryl spirolactam CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20080004304-A1 | Aryl Spirolactam Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004304-A1 | Aryl Spirolactam Cgrp Receptor Antagonists | BDKRB1, BDKRB2, CALCRL | CALCRL 3/4885RAB9A 1319/4885NPC1 609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.